$2.39
9.81% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Stock price

$2.39
-0.62 20.60% 1M
-1.74 42.13% 6M
+0.73 43.98% YTD
+1.81 308.55% 1Y
-23.89 90.91% 3Y
-27.26 91.94% 5Y
-27.26 91.94% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.26 9.81%
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Key metrics

Market capitalization $256.23m
Enterprise Value $106.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.51
P/S ratio (TTM) P/S ratio 3.62
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -42.30%
Revenue (TTM) Revenue $70.72m
EBIT (operating result TTM) EBIT $-136.59m
Free Cash Flow (TTM) Free Cash Flow $-137.19m
Cash position $274.27m
EPS (TTM) EPS $-2.40
P/E forward negative
P/S forward 3.53
EV/Sales forward 1.47
Short interest 4.68%
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

Buy
83%
Hold
17%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
71 71
42% 42%
100%
- Direct Costs 8.28 8.28
0% 0%
12%
65 65
43% 43%
92%
- Selling and Administrative Expenses 86 86
19% 19%
122%
- Research and Development Expense 113 113
23% 23%
160%
-133 -133
4% 4%
-188%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -137 -137
4% 4%
-193%
Net Profit -212 -212
19% 19%
-300%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
Seeking Alpha
6 days ago
ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Oper...
Neutral
PRNewsWire
9 days ago
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, ...
Neutral
PRNewsWire
10 days ago
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland , Nov. 5, 2024 /PRNew...
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 162
Founded 2011
Website www.adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today